Review
Multidisciplinary Sciences
Desye Gebrie, Desalegn Getnet, Tsegahun Manyazewal
Summary: This study aimed to compare the cardiovascular safety and efficacy of metformin-sodium-glucose cotransporter-2 inhibitors combination therapy versus metformin-sulphonylureas combination therapy in patients with type 2 diabetes. The results showed no significant difference in all-cause mortality, serious adverse events, and adverse events between the two therapies, but a significant reduction in hypoglycemia with the former. Participants on metformin-sodium glucose cotransporter-2 inhibitors combination therapy also demonstrated greater improvements in various metabolic indicators compared to those on metformin-sulphonylureas.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Jieying Liu, Dongmei Wang, Ziyan Xie, Lu Ding, Shunhua Li, Xuemei Ma, Jing Liu, Jing Ren, Cheng Xiao, Chunru Yang, Xinhua Xiao
Summary: The study assessed the protective effects of metformin and pioglitazone combination therapy on liver lipid metabolism in high-fat diet-fed mice and investigated the molecular mechanism. The results showed that the combination of pioglitazone and metformin significantly ameliorated metabolic disturbance and hepatic lipid profiles in HFD-induced mice, through regulating lipidomics profiling and RNA-seq analysis.
Article
Endocrinology & Metabolism
Seon Mee Kang, Han Mi Yun, Minji Sohn, Soo Lim
Summary: In patients with inadequately controlled type 2 diabetes treated with metformin and sulphonylurea, ipragliflozin showed better glycemic control and metabolic benefits compared to sitagliptin. Ipragliflozin treatment resulted in a significant decrease in glycated hemoglobin levels, improved glucose and fat metabolism, and enhanced vascular function. Both ipragliflozin and sitagliptin were found to be safe.
DIABETES OBESITY & METABOLISM
(2023)
Article
Pharmacology & Pharmacy
Dongmei Wang, Jieying Liu, Ling Zhong, Lu Ding, Qian Zhang, Miao Yu, Ming Li, Xinhua Xiao
Summary: The combined administration of metformin and pioglitazone has been shown to have protective effects on obese mice fed a high-fat diet. The study found that this combination therapy alters the gut microbiota and its metabolites, leading to improved glucolipid metabolism. The results provide novel evidence and potential targets for metformin and pioglitazone combination therapy in type 2 diabetes.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Fang Zhang, Lizhi Tang, Jing Li, Zhe Yan, Juan Li, Nanwei Tong
Summary: This study will conduct a 24-week open-label multicenter non-inferiority parallel-group RCT in Chinese adults with T2D comparing the combination therapy of pioglitazone/metformin and sitagliptin/metformin. Primary outcomes include HbA1c reduction, insulin level increase, and IR index change, while secondary outcomes focus on weight and VAT reduction, lipid profiles, and inflammatory markers. The results of this study aim to optimize treatment for Chinese adults with T2D characterized by IR.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY
(2021)
Review
Medicine, General & Internal
Awadhesh K. Singh, Ritu Singh, Partha Pratim Chakraborty
Summary: The study analyzed the advantages of metformin-based combination therapy over diabetes monotherapy, finding that combination therapy is more likely to achieve durable glycemic control with better tolerability.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Health Care Sciences & Services
Yan-Rong Li, Chi-Hung Liu, Wei-Chiao Sun, Pei-Yi Fan, Feng-Hsuan Liu, Tien-Hsing Chen, Victor Chien-Chia Wu, Chihung Lin, Ching-Chung Hsiao
Summary: This study found that the combination therapy of SGLT-2 inhibitors and Pio in T2DM patients did not increase the risk of bladder cancer and was associated with lower all-cause mortality.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, Erica Vetrano, Giulia Medicamento, Carlo Acierno, Luca Rinaldi, Aldo Marrone, Teresa Salvatore, Marcellino Monda, Celestino Sardu, Raffaele Marfella, Ferdinando Carlo Sasso
Summary: The study aimed to evaluate the effect of a combination therapy of empagliflozin + metformin vs. metformin monotherapy on the progression of NAFLD in type 2 diabetic patients. The results showed that after a 6-month follow-up, the combination therapy group had significant improvements in weight, glycated hemoglobin, ALT, CAP parameter, and steatosis degree compared to the control group.
Article
Endocrinology & Metabolism
Rui Sun, Lu Yuan, Yun Shen, Ziyang Shen, Bo Ding, Jianhua Ma
Summary: This study compared the effects of metformin, a fixed combination of metformin and pioglitazone, and dapagliflozin on insulin resistance in patients newly diagnosed with type 2 diabetes. The results showed that the fixed combination of metformin and pioglitazone provided greater improvement in insulin sensitivity compared to metformin alone, but had similar effects to dapagliflozin.
DIABETES METABOLIC SYNDROME AND OBESITY
(2023)
Article
Mathematical & Computational Biology
Ranjitha Guttapadu, Kalyani Korla, Safnaz Uk, Vamseedhar Annam, Purnima Ashok, Nagasuma Chandra
Summary: Type 2 Diabetes (T2D) is commonly treated with metformin, but many patients still develop complications. By analyzing transcriptomic data of T2D subjects, we constructed a protein-protein interaction network that captures the global perturbations in diabetes. We identified possible drug targets related to oxidative stress and hypercholesterolemia and proposed Probucol as a potential co-drug with metformin. In a rat model of diabetes, the combination of metformin and Probucol at 5:0.5 mg/kg effectively restored near-normal levels of glucose, lipids, and cholesterol.
NPJ SYSTEMS BIOLOGY AND APPLICATIONS
(2023)
Review
Medicine, General & Internal
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R. Webb, Melanie J. Davies
Summary: Type 2 diabetes accounts for nearly 90% of global diabetes cases, with an increasing number of affected individuals, particularly among young people. Early detection and proactive management are crucial for preventing complications and reducing mortality. Technology and precision medicine offer potential improvements to treatment outcomes but face significant barriers.
Article
Pharmacology & Pharmacy
Umair Ilyas, Muhammad Asif, Minglian Wang, Reem Altaf, Hajra Zafar, Mirza Muhammad Faran Ashraf Baig, Ana Claudia Paiva-Santos, Muhammad Abbas
Summary: Pioglitazone (PGZ) is utilized as a therapeutic agent in the management of type 2 diabetes. This study aimed to develop and optimize PGZ-containing nanostructured lipid carriers (NLCs) as a drug delivery system. The optimized PGZ-NLCs showed excellent physical and chemical properties, and significantly extended release compared to unformulated PGZ.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Maddalena Angela Di Lellis
Summary: Most recommendations for the treatment of blood sugar levels in people with type 2 diabetes suggest metformin as the first-line medication, which can be supplemented by a second medication if needed. Currently, there are only a few comparative studies available to guide the choice of a second blood sugar-lowering medication. The GRADE Study Research Group evaluated the effectiveness of 4 agents for lowering blood sugar.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
(2023)
Article
Medicine, General & Internal
Natthida Sriboonvorakul, Wirichada Pan-Ngum, Kittiyod Poovorawan, Sant Muangnoicharoen, Lauren M. Quinn, Bee K. Tan
Summary: The study on amino acid profiles in individuals with Type 2 diabetes mellitus in Thailand revealed lower levels of branched-chain amino acids and tyrosine, while phenylalanine was higher in the multi-treated group. This suggests a potential role for branched-chain amino acid supplementation in improving diabetes management.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Clinical Neurology
Huan Yu, Ruotong Yang, Junhui Wu, Siyue Wang, Xueying Qin, Tao Wu, Yonghua Hu, Yiqun Wu
Summary: This study suggests that metformin is associated with a lower risk of depression. When compared with other oral hypoglycemic agents, the metformin group had a reduced incidence of depression.
JOURNAL OF AFFECTIVE DISORDERS
(2022)